Nice. Founders on trend…

I talk a lot about the incredible platform we’re building at @RecursionPharma, but nothing beats hearing from the brilliant scientists who use it every day. That’s why I love this video with @OncNTechStuff. Chase is part of the team that uncovered the initial insight for our.

Having spent most of my summer working from our London office, I’ve had the chance to see firsthand what makes this city so special. It’s more than just a place to set up a business; it’s a vibrant hub where brilliant minds in tech and life sciences are collaborating to define

Submit your questions here:

Today, we announced our Q2 updates, and I'm proud of the progress across our platform, pipeline and partnerships. Our vision at @RecursionPharma isn't just to discover new medicines; it's to fundamentally create a better way to do it, powered by our integrated, end-to-end AI

Our culture at @RecursionPharma isn't a 'nice-to-have' – it's a strategic imperative. With a mission as ambitious as ours, the values and mindset that guide our actions are just as important as the science and technology that power our platform. After all, Recursion is one big.

Each of us at @RecursionPharma have our own reasons for doing what we do. For some, it's a chance to take a swing at diseases that stole a loved one away from us too early. For others, it's the challenge of working on really hard problems with really smart people. And for others.

Some sort of fire near St Pancras happening now.

The current climate in biotech demands incredibly tough choices, and like many, we at @RecursionPharma recently faced one of the hardest. If you've been in a leadership seat, you know these decisions carry immense weight – yet they are also essential to achieving your mission.

As part of our ongoing commitment to deliver maximal impact from the Recursion 2.0 platform, the maturation of AI tools and ongoing friction in biotech capital markets, today we are updating our tactics at Recursion to continue to deliver on our ambitious strategy. 🔹 Optimized.

In my JPM presentation in January, I talked about the work happening at @RecursionPharma to help build a virtual cell, spanning the atomistic scale to the protein scale to the pathway scale all the way up to the patient scale. While Recursion is leading the field with in-house

I recently had a great conversation with David Bearss on the @GoodMedicinePod, reflecting on Recursion's journey over the past 11+ years, the current state of TechBio, and where the industry is headed next. David is a serial entrepreneur and experienced drug hunter who shares my.

One of my favorite things when guests visit our headquarters in Salt Lake is to take them for a tour in our labs. Seeing our robots in action, running millions of experiments every week, generating petabytes of data for training AI models (the equivalent of my entire PhD's worth

For over a decade at @RecursionPharma, we've been driven by a core belief: truly understanding biology, and ultimately accelerating drug discovery, starts with building the right datasets. Every week we run millions of experiments in our highly automated wet lab to generate this

Such a delight to continue working with @LinaZNilsson as our Chief Platform Officer @RecursionPharma where she will steward our Recursion OS, ensuring the machine continues to improve, that it is fully integrated into all we do and that we invest appropriately into the.

IYKYK

RT @RecursionPharma: Today, we’re reporting business updates and first quarter 2025 financial results. 🔹 Key updates include:. ▪️ Prioriti….

Big moments of focus often follow big bets. Over the last few years, we’ve been running one of the most ambitious experiments in the history of biotechnology: to decode biology with unprecedented scale and precision through the integration of automation, AI, and wet lab science.

Today, we announced the first patient dosed in @RecursionPharma’s Phase 1 trial of REC-3565 (EXCELERIZE) – a potential best-in-class MALT1 inhibitor – marking an important step forward in our efforts to improve outcomes for patients with B-cell malignancies who currently have